Bladder cancer used to be a disease with very few effective treatment options. That was until two new strategies came on the scene: immunotherapies and antibody drug conjugates. These approaches have changed the way doctors treat bladder cancer, and prolonged the lives of many patients. Dr. Tom Powles, head of Barts Cancer Institute, tells Chuck and Alicia about his work on developing these treatments and where he hopes science will take us next.

Radioligand therapy is a form of precise cancer treatment that targets specific cells with a radioactive substance. It’s used to treat prostate cancer and some types of neuroendocrine cancer, delivering powerful results with minimal impact on patient quality of life. Dr. Michael Morris helped develop radioligands for prostate cancer, and he tells Chuck and Alicia about the huge promise he sees in these treatments going forward.

A lot of cancers don’t get diagnosed until the disease is somewhat advanced. Dr. Bea Bakshi founded her company, C the Signs, to change that. They use artificial intelligence to comb through medical records and identify when a patient should be screened for cancer – and it catches disease far earlier than a human doctor could. She tells Chuck about their success integrating into the National Health System in the UK, and their plans to launch in the United States.